Conversion from cyclosporin (Neoral (R)) to tacrolimus (Prograf (R)) in renal allograft recipients with chronic graft nephropathy: results of an observational study
Gj. Morris-stiff et al., Conversion from cyclosporin (Neoral (R)) to tacrolimus (Prograf (R)) in renal allograft recipients with chronic graft nephropathy: results of an observational study, TRANSPLAN I, 12(4), 1999, pp. 288-292
To evaluate the role of tacrolimus in the treatment of Chronic Graft Nephro
pathy (CGN), a pilot cross-sectional study was performed on 14 patients wit
h deteriorating renal function and biopsy-proven CGN. Maintenance therapy w
as switched from cyclosporin to tacrolimus, and results of conversion on al
lograft function were assessed by estimated glomerular filtration rate (GFR
) and clinical outcome. Minimum follow-up was 15 months. TWO distinctive re
sponse patterns emerged: (i) continuing deterioration of renal function wit
h no apparent benefit over the projected trend of GFR (nine patients), and
(ii) unequivocal change in the GFR trend line equation with reduced rate of
deterioration in one patient and sustained improvement of GFR in four pati
ents (reversal of downward trend). Five out of 14 patients (36%) benefited
from replacing Neoral with Prograf. All five patients exceeded their estima
ted time of return to dialysis by a median of 41 weeks (range: 29-52) and t
heir grafts continue to function.